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individuals using these methods interchangeably since 
these biomarkers could reﬂ ect diﬀ erent processes of 
Alzheimer’s disease or might become abnormal at a 
diﬀ erent stage of the disease process. Moreover, results 
might be diﬀ erent when molecular CSF measures 
are used. Tau PET imaging will also be an important 
addition in the near future. It should be noted that the 
classiﬁ cation in biomarker states also largely depends 
on the choice of biomarker cutoﬀ s and some individuals 
might have biomarker values close to a cutoﬀ , making a 
shift to a new biomarker state less clinically meaningful. 
Overall, the study by Jack and colleagues9 provides 
an important new step towards our understanding 
of dynamic processes taking place in the brain during 
normal ageing and in Alzheimer’s disease and other 
neurodegenerative disorders. Additional comparable 
studies with longer follow-up are needed.
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MRI quantiﬁ es neuromuscular disease progression
Several studies provide compelling support for the 
use of MRI as a sensitive non-invasive method to 
assess skeletal muscle disease progression in various 
neuromuscular diseases, including Duchenne muscular 
dystrophy1,2 and limb girdle muscular dystrophy type 2I.3 
In The Lancet Neurology, Jasper Morrow and colleagues4 
now report the sensitivity of MRI to track disease 
progression in 20 patients with Charcot-Marie-Tooth 
disease 1A and 20 patients with inclusion body myositis.
The investigators used a comprehensive study design 
that included magnetic resonance measures of muscle 
fat fraction, transverse relaxation time constant (T2), 
and magnetisation transfer ratio (MTR), along with 
relevant clinical functional tests (lower limb myometry, 
Medical Research Council score, Short-Form 36 Quality 
of Life Score, and Charcot-Marie-Tooth examination 
score or inclusion body myositis functional rating scale). 
In this study, the validity of the magnetic resonance 
measures was supported by strong correlations with 
clinical functional measures and the responsiveness 
to disease progression over 1 year was shown to be 
better with MRI than with the clinical functional tests. 
Notably, standardised response mean values were 
greater than 1 in inclusion body myositis and greater 
than 0·8 in Charcot-Marie-Tooth disease 1A, indicating 
that magnetic resonance measures are highly sensitive 
to disease progression and more responsive than 
established clinical measures. Even though Charcot-
Marie-Tooth disease 1A progresses slowly, magnetic 
resonance measures detected substantial increases 
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in disease pathological changes in 1 year. Thus, the 
encouraging results of Morrow and colleagues’ 
study might have a profound eﬀ ect on clinical trials, 
potentially leading to a need for fewer participants to 
show eﬃ  cacy or futility, shorter trials, and ultimately 
more rapid approval of treatments. An additional 
advantage of magnetic resonance measures compared 
with timed functional and strength measures, which are 
highly relevant to paediatric neuromuscular diseases, is 
that they are not dependent on participant motivation, 
an issue that has been of concern in Duchenne muscular 
dystrophy trials.5 
Along with showing that MRI is a sensitive measure of 
disease progression in Charcot-Marie-Tooth disease 1A 
and inclusion body myositis, Morrow and colleagues also 
report that MRI-measured T2 and MTR are abnormal in 
these diseases even when fat fraction values are within 
normal limits. The authors interpret this to suggest that 
tissue water distribution changes before fat inﬁ ltration. 
Because MRI-measured T2 and MTR are aﬀ ected by 
both fat and water content, the interpretation of these 
measures can be diﬃ  cult in the context of neuromuscular 
diseases, and several analysis approaches are being 
developed to address this concern.6–8 Alternatively, 
magnetic resonance spectroscopy (MRS) could be used to 
more directly measure ¹H₂O T2 (ﬁ gure) and MTR, and this 
would avoid the inﬂ uence of fat.9 This method has already 
been applied to neuromuscular diseases10,11 ¹H₂O T2 has 
been shown to diﬀ erentiate boys with Duchenne muscular 
dystrophy and healthy individuals, even at a young age, 
when muscle fat fraction levels are normal.10 Furthermore, 
¹H₂O T2 measured with MRS decreases with corticosteroid 
treatment in Duchenne muscular dystrophy, presumably 
because of reduced inﬂ ammation.11  Therefore, although 
lacking in spatial resolution, MRS is a high-ﬁ delity 
approach to calculate  ¹H₂O T2 and MTR measurements in 
neuromuscular diseases. 
In view of the low prevalence of neuromuscular 
diseases, standardisation of methods over several 
sites will be crucial to the successful implementation 
of magnetic resonance biomarkers in clinical trials. 
Although challenging, when standardised protocols are 
carefully implemented across sites, several important 
magnetic resonance measures can be reproducibly 
obtained, including MRI-measured T2 and MRS 
measures of fat fraction and ¹H₂O T2.12 Similar to 
neuroimaging and musculoskeletal studies, for larger 
trials, incorporation of an infrastructure that enables 
automated or semi-automated processing, analysis, and 
quality control procedures that can detect and correct for 
system deviations, including instrument modiﬁ cations 
and upgrades, will be particularly important. 
Importantly, Morrow and colleagues showed the 
eﬀ ectiveness of monitoring disease progression using 
magnetic resonance sequences commonly available 
on clinical scanners.  Although the measures used were 
highly eﬀ ective in tracking progression, future studies 
might include some developments. For example, 
the accuracy of fat fraction from the Dixon fat-water 
imaging sequence might be further improved by 
correcting for T2*, accounting for noise bias, and using 
a multipeak Dixon model speciﬁ c to skeletal muscle.13,14 
As suggested by Morrow and colleagues, the optimum 
outcome measures will depend on the pathophysiology, 
stage of disease, muscles aﬀ ected, and intervention 
to be tested. This could include diﬀ erent types of 
magnetic resonance measures and analysis procedures. 
For example, targeting of speciﬁ c muscles might be 
optimum for certain stages of a particular disease. Also, 
use of large regions of interest that encompass the 
entire muscle might be needed to detect pathological 
changes and improve responsiveness in some diseases, 
by contrast with small portions of the muscle, as used by 
Morrow and colleagues to measure T2 and MTR.  
Overall, this study by Morrow and colleagues clearly 
shows the value of MRI to monitor disease progression 
and sets the stage for its potential use in clinical trials 
Figure: MRI and magnetic resonance spectroscopy of skeletal muscle in Duchenne muscular dystrophy
(A) Magnetic resonance spin echo axial image of the lower leg of an 11-year-old boy with Duchenne muscular 
dystrophy. The white box indicates the position of voxel placement in which proton magnetic resonance 
spectroscopy data were obtained from the soleus muscle. (B) Single voxel spectroscopic relaxometry data were 
acquired using a non-linear increase in echo time (range 11–288 ms). Fitting the decay curve of the ¹H₂O peak to a 
mono-exponential model enabled a high conﬁ dence measure of ¹H₂O transverse relaxation time independent of 
lipid. In this example, ¹H₂O transverse relaxation time was calculated to be 36·5 ms in the boy with Duchenne 
muscular dystrophy, which is substantially longer than that of a typical unaﬀ ected boy of a similar age (27–29 ms).9 
The proton spectra are displayed with water referenced at 4·7 parts per million (ppm) and the smaller resonances 
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for Charcot-Marie-Tooth disease 1A and inclusion 
body myositis.  With increased evidence of the validity 
and sensitivity of magnetic resonance biomarkers 
in neuromuscular diseases, the path for biomarker 
qualiﬁ cation (eg, their approval by the Food and Drug 
Administration) should be carefully explored, with the 
ultimate goal of using magnetic resonance measures as 
surrogate endpoints in clinical trials.
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